Platform Technology for Single, Sustained-release Combination Drug to Improve Compliance

Patients with certain conditions such as Parkinson’s Disease are required to take medication several times daily. Polypharmacy has been associated with greater health care costs and an increased risk of adverse drug events (ADEs), drug-interactions, and medication non-adherence amongst many other negative consequences.

This technology platform reformulates commercial pharmaceuticals with poor oral bioavailability profiles to cut the frequency of administering medication and improve treatment outcomes in patients.

The technology platform consists of proprietary multiple drug encapsulation technology and, extended and tunable release drug profile of various drugs.

The encapsulation technology leverages on floating technology to prolong gastric-retention time of drugs. The stomach then acts as reservoir and allow for slow absorption and extended release of drugs. Different drugs i.e., hydrophilic and hydrophobic, can be formulated into one single drug capsule and released uniformly.

Clinical pipeline includes candidates for Parkinson’s Disease, cardiovascular disease, and infectious disease currently at pre-clinical stage.

Therapeutics

• As multiple-drug-in-one capsule or improved drug profile to decrease the need for frequent drug administration and improve medical adherence i.e., one drug instead of Stalevo-Sinemet combi up to 6 times a day for Parkinson’s Disease.

Nutraceuticals and Supplements

• Technology can also be used to encapsulate natural and other related compounds for tunable, sustained release of supplements or nutraceuticals with more than one ingredient

Treatment market value for PD is expected to rise to US$11.5billion by 2029 at a CAGR of 12.6%.  In addition, as a platform technology, this formulation seeks to improve patient medication compliance by providing sustained release of polypharmacies for the management of chronic diseases. Medical non-compliance in the USA alone costs the health care system $300 billion annually.

Decreases the need for multiple medications several times a day and ADEs, and healthcare cost; improves medical adherence. For PD patients, this technology will also mitigate levodopa-induced dyskinesia, which affects 90% of PD patients in the latter years of their treatment.